Zydus Lifesciences Limited announced it has received final approval from the United States Food and Drug Administration (USFDA) for Diltiazem Hydrochloride Tablets USP, in strengths of 30 mg, 60 mg, 90 mg, and 120 mg.
Zydus Life stock gained on Monday, and was trading up 0.7% at Rs 942 on BSE in the morning session.
The drug is indicated for managing chronic stable angina and angina due to coronary artery spasm. It is a calcium-channel blocker that relaxes blood vessels, reducing the heart's workload and increasing blood and oxygen supply to the heart muscle.
The tablets will be manufactured at Zydus Lifesciences Ltd, Baddi, Himachal Pradesh. According to IQVIA MAT June 2025 data, Diltiazem Hydrochloride Tablets had annual sales of USD 13.9 million in the United States.
As of July 31, 2025, the group has 423 approvals and has filed 483 ANDAs since FY 2003-04.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
